# Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

> **NCT04644068** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 702 (actual)

## Conditions studied

- Ovarian Cancer
- Breast Cancer
- Pancreatic Cancer
- Prostate Cancer
- Additional Indications Below for Module 4 and 5
- Non-small Cell Lung Cancer
- Colorectal Cancer
- Bladder Cancer
- Gastric Cancer
- Biliary Cancer
- Cervical Cancer
- Endometrial Cancer
- Small Cell Lung Cancer Only in Module 5

## Interventions

- **DRUG:** AZD5305
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** T- Dxd
- **DRUG:** Dato-DXd
- **DRUG:** Camizestrant

## Key facts

- **NCT ID:** NCT04644068
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-11-12
- **Primary completion:** 2027-05-28
- **Final completion:** 2027-05-28
- **Target enrollment:** 702 (ACTUAL)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04644068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04644068, "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04644068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*